??????????????????, ???????????????????????????????Unfit sufferers also have the alternative of venetoclax furthermore obinutuzumab (VO) as frontline therapy. This is based on a period III trial that in contrast VO with ClbO in elderly/unfit individuals.113 VO was remarkable with regard to response level and progression-free of charge survival, and